RecruitingPhase 2Phase 3NCT07804849

Oral Verapamil Among Newly Diagnosed Children and Adolescents With Type 1 Diabetes

Efficay and Safety of Oral Verapamil on Glycemic Metrics and ß-cell Reserve Among Newly Diagnosed Children and Adolescents With Type 1 Diabetes

Sponsor

Ain Shams University

Enrollment

70 participants

Start Date

Aug 20, 2026

Study Type

INTERVENTIONAL

Conditions

Type 1 Diabetes Mellitus

Summary

Type 1 diabetes (T1D) in children involves autoimmune destruction of pancreatic ß- cells, leading to insulin deficiency. Verapamil is an L-type calcium channel blocker that has been used for decades to treat hypertension and certain cardiac conditions. Recent research has revealed its potential as a ß- cell-protective agent. Hence this study will evaluate the effect of once-daily oral verapamil on pancreatic ß- cell reserve , glycemic metrics and daily insulin requirements in children and adolescents with T1D.

Eligibility

Min Age: 10 YearsMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called Verapamil oral for people with type 1 diabetes mellitus. The study is currently recruiting participants at 1 location. People eligible for this study include aged 10 Years to 18 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.